Pro-survival and anti-apoptotic properties of androgen receptor signaling by oxidative stress promote treatment resistance in prostate cancer.
暂无分享,去创建一个
[1] E. Martinelli,et al. Gender Influences the Class III and V β-Tubulin Ability to Predict Poor Outcome in Colorectal Cancer , 2012, Clinical Cancer Research.
[2] M. Parker,et al. Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression , 2008, Oncogene.
[3] E. Hurt,et al. Effects of Manganese Superoxide Dismutase Silencing on Androgen Receptor Function and Gene Regulation: Implications for Castration-Resistant Prostate Cancer , 2008, Clinical Cancer Research.
[4] M. Gleave,et al. Dysregulation of Sterol Response Element-Binding Proteins and Downstream Effectors in Prostate Cancer during Progression to Androgen Independence , 2004, Cancer Research.
[5] S. Yeh,et al. Identification of 3',5'-cyclic adenosine monophosphate response element and other cis-acting elements in the human androgen receptor gene promoter. , 1994, Molecular endocrinology.
[6] J. Manola,et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. , 2004, JAMA.
[7] N. Sharifi,et al. SOD Mimetics: A Novel Class of Androgen Receptor Inhibitors That Suppresses Castration-Resistant Growth of Prostate Cancer , 2011, Molecular Cancer Therapeutics.
[8] Yuet-Kin Leung,et al. Androgenic regulation of oxidative stress in the rat prostate: involvement of NAD(P)H oxidases and antioxidant defense machinery during prostatic involution and regrowth. , 2003, The American journal of pathology.
[9] C. Bevan,et al. The Role of Androgen Receptor Mutations in Prostate Cancer Progression , 2009, Current genomics.
[10] K. Kuroiwa,et al. Androgen receptor signaling regulates cell growth and vulnerability to doxorubicin in bladder cancer. , 2012, The Journal of urology.
[11] G. Wilding,et al. Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. , 1997, Journal of the National Cancer Institute.
[12] Huiqing Yuan,et al. Involvement of transcription factor Sp1 in quercetin-mediated inhibitory effect on the androgen receptor in human prostate cancer cells. , 2005, Carcinogenesis.
[13] B. Wilson,et al. Androgen induces adaptation to oxidative stress in prostate cancer: implications for treatment with radiation therapy. , 2007, Neoplasia.
[14] K. Kuroiwa,et al. Statins reduce the androgen sensitivity and cell proliferation by decreasing the androgen receptor protein in prostate cancer cells , 2011, The Prostate.
[15] T. Nishiyama. Androgen deprivation therapy in combination with radiotherapy for high-risk clinically localized prostate cancer , 2012, The Journal of Steroid Biochemistry and Molecular Biology.
[16] J. Andersen,et al. Oxidative stress in neurodegeneration: cause or consequence? , 2004, Nature Reviews Neuroscience.
[17] Geun-Young Kim,et al. Androgen receptor is up-regulated by a BLT2-linked pathway to contribute to prostate cancer progression. , 2012, Biochemical and biophysical research communications.
[18] Peng Huang,et al. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? , 2009, Nature Reviews Drug Discovery.
[19] P. Nelson,et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. , 2008, Cancer research.
[20] K. Tomer,et al. Testosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate Cancer , 2005, Clinical Cancer Research.
[21] T. Uchiumi,et al. Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression , 2010, Oncogene.
[22] Ricky A. Sharma,et al. Androgen manipulation alters oxidative DNA adduct levels in androgen-sensitive prostate cancer cells grown in vitro and in vivo. , 2008, Cancer letters.
[23] H. Scher,et al. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] R. Robison,et al. The role of oxidative stress in prostate cancer , 2012, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.
[25] Zhiyong Guo,et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. , 2009, Cancer research.
[26] H. Izumi,et al. Twist and p53 reciprocally regulate target genes via direct interaction , 2008, Oncogene.
[27] M. Gleave,et al. Timing Is Everything: Preclinical Evidence Supporting Simultaneous Rather Than Sequential Chemohormonal Therapy for Prostate Cancer , 2005, Clinical Cancer Research.
[28] P. Ray,et al. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. , 2012, Cellular signalling.
[29] K. Chi,et al. Beyond Castration—Defining Future Directions in the Hormonal Treatment of Prostate Cancer , 2012, Hormones and Cancer.
[30] M. Zelefsky. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial , 2006 .
[31] M. Kattan,et al. Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] 小川 和彦. What's going on 放射線 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. JAMA. 2004;292:821-7. PMID:15315996--放射線治療 , 2005 .
[33] C. Pham,et al. Upregulation of Twist-1 by NF-κB Blocks Cytotoxicity Induced by Chemotherapeutic Drugs , 2007, Molecular and Cellular Biology.
[34] T. Ratliff. High molecular mass proteome of androgen-independent prostate cancer. , 2005, Journal of Urology.
[35] Endothelin‐1 enhances the expression of the androgen receptor via activation of the c‐myc pathway in prostate cancer cells , 2009, Molecular carcinogenesis.
[36] M. Gleave,et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. , 2008, Cancer research.
[37] L. Chung,et al. Activation of Androgen Receptor, Lipogenesis, and Oxidative Stress Converged by SREBP-1 Is Responsible for Regulating Growth and Progression of Prostate Cancer Cells , 2011, Molecular Cancer Research.
[38] Rocío Martín,et al. Quantitative and immunohistochemical evaluation of PCNA, androgen receptors, apoptosis, and Glutathione‐S‐Transferase P1 on preneoplastic changes induced by cadmium and zinc chloride in the rat ventral prostate , 2005, The Prostate.
[39] Christopher U. Jones,et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. , 2011, The New England journal of medicine.
[40] M. Shiota,et al. Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target. , 2011, Journal of molecular endocrinology.
[41] D. Coppola,et al. Ack1-mediated Androgen Receptor Phosphorylation Modulates Radiation Resistance in Castration-resistant Prostate Cancer* , 2012, The Journal of Biological Chemistry.
[42] S. Kato,et al. Androgen receptor counteracts Doxorubicin-induced cardiotoxicity in male mice. , 2010, Molecular endocrinology.
[43] D. Tindall,et al. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. , 2008, Cancer research.
[44] A. Ravaud,et al. A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial. , 2012, European journal of cancer.
[45] Masataka Nakamura,et al. Unique CCT repeats mediate transcription of the TWIST1 gene in mesenchymal cell lines. , 2007, Biochemical and biophysical research communications.
[46] R. Vessella,et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. , 2009, Cancer research.
[47] H. Izumi,et al. Twist promotes tumor cell growth through YB-1 expression. , 2008, Cancer research.
[48] M. Landström,et al. Combined castration and fractionated radiotherapy in an experimental prostatic adenocarcinoma. , 1997, International journal of radiation oncology, biology, physics.
[49] B. Djavan,et al. Androgen deprivation therapy. , 2008, Reviews in urology.
[50] Yi Lu,et al. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. , 2006, Cancer research.
[51] Xu Wang,et al. Long-term mequindox treatment induced endocrine and reproductive toxicity via oxidative stress in male Wistar rats. , 2011, Toxicology and applied pharmacology.
[52] R. Vessella,et al. Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.
[53] C. Woo,et al. Role of the BLT2, a leukotriene B4 receptor, in Ras transformation , 2004, Oncogene.
[54] J. Ni,et al. Induction of Androgen Receptor Expression by Phosphatidylinositol 3-Kinase/Akt Downstream Substrate, FOXO3a, and Their Roles in Apoptosis of LNCaP Prostate Cancer Cells* , 2005, Journal of Biological Chemistry.
[55] P. Light,et al. Reactive oxygen species directly modify sodium-calcium exchanger activity in a splice variant-dependent manner. , 2009, Journal of molecular and cellular cardiology.
[56] R. Touyz,et al. Redox signaling in hypertension. , 2006, Cardiovascular research.
[57] J. Kumar,et al. Activation of a non-genomic Pim-1/Bad-Pser75 module is required for an efficient pro-survival effect of Bcl-xL induced by androgen in LNCaP cells. , 2011, The international journal of biochemistry & cell biology.
[58] S. Egawa,et al. High molecular mass proteome of androgen‐independent prostate cancer , 2005, Proteomics.
[59] S. Koul,et al. Oxidative stress in prostate cancer. , 2009, Cancer letters.
[60] M. Shiota,et al. Androgen receptor cofactors in prostate cancer: potential therapeutic targets of castration-resistant prostate cancer. , 2011, Current cancer drug targets.
[61] Goedele Roos,et al. Protein sulfenic acid formation: from cellular damage to redox regulation. , 2011, Free radical biology & medicine.
[62] Y. Oshika,et al. P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.
[63] P N Leigh,et al. Androgen‐induced up‐regulation of tubulin isoforms in neuroblastoma cells , 2001, Journal of neurochemistry.
[64] Arturo Molina,et al. Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.
[65] C. D’Este,et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. , 2005, The Lancet. Oncology.
[66] K Botzenhart,et al. Reactive Oxygen Species , 2014 .
[67] Kurt Miller,et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.
[68] M. Kattan,et al. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. , 2001, Urology.
[69] T. Golub,et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. , 2006, Cancer research.
[70] Haishan Xu,et al. ENaC alpha-subunit variants are expressed in lung epithelial cells and are suppressed by oxidative stress. , 2007, American journal of physiology. Lung cellular and molecular physiology.
[71] K. Kuroiwa,et al. Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression. , 2011, Endocrine-related cancer.
[72] Jung-A Choi,et al. Pro-survival of estrogen receptor-negative breast cancer cells is regulated by a BLT2-reactive oxygen species-linked signaling pathway. , 2010, Carcinogenesis.
[73] J. Mayo,et al. Upregulation of manganese superoxide dismutase (SOD2) is a common pathway for neuroendocrine differentiation in prostate cancer cells , 2009, International journal of cancer.
[74] N. Socci,et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor , 2010, Proceedings of the National Academy of Sciences.
[75] A. Hanlon,et al. Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth. , 2003, International journal of radiation oncology, biology, physics.
[76] H. Friess,et al. BLT2 is expressed in PanINs, IPMNs, pancreatic cancer and stimulates tumour cell proliferation , 2008, British Journal of Cancer.
[77] T. Kawai,et al. Oxidative stress-induced alternative splicing of transformer 2beta (SFRS10) and CD44 pre-mRNAs in gastric epithelial cells. , 2009, American journal of physiology. Cell physiology.
[78] D. Tindall,et al. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. , 2007, Endocrine reviews.
[79] D. Tindall,et al. Androgen Action in Prostate Cancer , 2009, Hormones & cancer.
[80] R. Ge,et al. Mono-(2-ethylhexyl) phthalate affects the steroidogenesis in rat Leydig cells through provoking ROS perturbation. , 2012, Toxicology in vitro : an international journal published in association with BIBRA.
[81] Seiji Naito,et al. Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth. , 2009, Cancer research.
[82] L. Chung,et al. Reactive oxygen species mediate androgen receptor‐ and serum starvation‐elicited downstream signaling of ADAM9 expression in human prostate cancer cells , 2007, The Prostate.
[83] P. Nelson,et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. , 2010, The Journal of clinical investigation.
[84] W. Gerald,et al. NF-kappaB regulates androgen receptor expression and prostate cancer growth. , 2009, The American journal of pathology.
[85] E. Suzuki,et al. Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer. , 2011, The Journal of urology.
[86] Miao-Fen Chen,et al. The radiation response of hormone-resistant prostate cancer induced by long-term hormone therapy. , 2007, Endocrine-related cancer.
[87] R. Ricks. Radiation response. , 1989, Emergency.
[88] Seiji Naito,et al. Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer. , 2011, Free radical biology & medicine.
[89] R. Zhao,et al. Thioredoxin 1 as a subcellular biomarker of redox imbalance in human prostate cancer progression. , 2010, Free radical biology & medicine.
[90] C. D’Este,et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. , 2011, The Lancet. Oncology.
[91] K. Burnstein,et al. Multiple androgen response elements and a Myc consensus site in the androgen receptor (AR) coding region are involved in androgen-mediated up-regulation of AR messenger RNA. , 1999, Molecular endocrinology.
[92] D. Bostwick,et al. Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer , 2000, Cancer.
[93] A. Abdel‐Mageed,et al. Studies on molecular mechanisms of growth inhibitory effects of thymoquinone against prostate cancer cells: role of reactive oxygen species , 2010, Experimental biology and medicine.
[94] J. Trapman,et al. Two different, overlapping pathways of transcription initiation are active on the TATA-less human androgen receptor promoter. The role of Sp1. , 1993, The Journal of biological chemistry.
[95] A. Renshaw,et al. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. , 2008, JAMA.
[96] D. Mackenzie,et al. The curcumin analog ca27 down‐regulates androgen receptor through an oxidative stress mediated mechanism in human prostate cancer cells , 2012, The Prostate.
[97] Desok Kim,et al. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. , 1998, Cancer research.
[98] T. Uchiumi,et al. Peroxiredoxin 2 in the nucleus and cytoplasm distinctly regulates androgen receptor activity in prostate cancer cells. , 2011, Free radical biology & medicine.
[99] D. Piscitelli,et al. Identification of 3',5'-cyclic adenosine monophosphate-inducible nuclear factors binding to the human urokinase promoter in mouse Sertoli cells. , 1993, Molecular endocrinology.
[100] L. Chung,et al. Androgen Receptor Survival Signaling Is Blocked by Anti-β2-microglobulin Monoclonal Antibody via a MAPK/Lipogenic Pathway in Human Prostate Cancer Cells* , 2010, The Journal of Biological Chemistry.
[101] S. Pang,et al. Gene expression profiling of androgen deficiency predicts a pathway of prostate apoptosis that involves genes related to oxidative stress. , 2002, Endocrinology.
[102] E. Messing,et al. Androgen deprivation therapy for prostate cancer: Current status and future prospects , 2004, The Prostate.
[103] Y. Sasaguri,et al. Programmed Cell Death Protein 4 Down-regulates Y-Box Binding Protein-1 Expression via a Direct Interaction with Twist 1 to Suppress Cancer Cell Growth , 2009 .
[104] B. Yankner,et al. The aging stress response. , 2010, Molecular cell.
[105] H. Uramoto,et al. p73 Interacts with c-Myc to Regulate Y-box-binding Protein-1 Expression* , 2002, The Journal of Biological Chemistry.
[106] A. Acharya,et al. Redox regulation in cancer , 2010, Oxidative medicine and cellular longevity.
[107] E. Bruckheimer,et al. TGF‐β signaling and androgen receptor status determine apoptotic cross‐talk in human prostate cancer cells , 2008, The Prostate.
[108] Yajun Yi,et al. Molecular Alterations in Primary Prostate Cancer after Androgen Ablation Therapy , 2005, Clinical Cancer Research.
[109] T. Triche,et al. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. , 2009, Cancer cell.
[110] A. Gao,et al. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[111] E. Sato,et al. [Reactive oxygen]. , 2002, Nihon eiseigaku zasshi. Japanese journal of hygiene.
[112] A. Zietman,et al. Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system. , 1997, International journal of radiation oncology, biology, physics.
[113] D. Tindall,et al. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. , 2002, Cancer research.
[114] S. Balk. Increased Expression of Genes Converting Adrenal Androgens to Testosterone in Castration-Recurrent Prostate Cancer , 2009 .